Korea Arlico Pharm Co.,Ltd. (260660.KQ) Stock
Korea Arlico Pharm Co.,Ltd.

Company profile
Korea Arlico Pharm reported revenue of 201.20 billion KRW for fiscal year 2025, up 5.7% from fiscal year 2024. Our analysis of its filings shows revenue growing from 187.15 billion KRW in fiscal year 2023 to 201.20 billion KRW in fiscal year 2025, 3.7% a year on average.
What stands out
- It reported a net loss in each of its last 2 fiscal years, after a profit of 3.06 billion KRW in fiscal year 2023; the loss narrowed from 5.36 billion KRW in fiscal year 2024 to 605.35 million KRW in fiscal year 2025.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Korea Arlico Pharm Co.,Ltd.
Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. The company provides ETC, OTC, medical device, and other products; and active ingredients. It offers products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.
Largest shareholders
- Hang-Gu Lee33.41 %33.41%
- Korea Arlico Pharm Co.,Ltd.2.05%
- Ji-sook Lee1.095 %1.09%
- Ji-Hye Lee1.095 %1.09%
- Jin-bok Lee1.095 %1.09%
Share of the company, as of September 25, 2026
Leadership
- Hang-Gu Lee — CEO & Representative Director, 64
- Dae-Hoon Kim — President
- Dong Soo Kim — MD & Internal Accounting Manager
How much revenue does Korea Arlico Pharm make?
Korea Arlico Pharm reported 201.20 billion KRW in revenue for fiscal year 2025, up 5.7% from 190.44 billion KRW in fiscal year 2024.
What companies are similar to Korea Arlico Pharm?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jin Yang Pharmaceutical Co., Ltd. (007370.KQ), Myungmoon Pharm co.,Ltd (017180.KS), Bcworld Pharm. Co., Ltd. (200780.KQ), Sanigen (188260.KQ).
Has Korea Arlico Pharm made a profit in recent years?
Net income by fiscal year: FY2021, 4.93 billion KRW; FY2022, 8.03 billion KRW; FY2023, 3.06 billion KRW; FY2024, a loss of 5.36 billion KRW; FY2025, a loss of 605.35 million KRW. It reported a net loss in 2 of these 5 years.
How has Korea Arlico Pharm's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 140.16 billion KRW; FY2022, 167.74 billion KRW; FY2023, 187.15 billion KRW; FY2024, 190.44 billion KRW; FY2025, 201.20 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Korea Arlico Pharm Co.,Ltd. (260660.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/260660.KQ